Oxemia 100 Tablet contains Desidustat 100mg, a potent hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) indicated for the treatment of anemia associated with chronic kidney disease (CKD). By stabilizing hypoxia-inducible factors, Desidustat promotes endogenous erythropoietin production, thereby enhancing erythropoiesis and improving hemoglobin levels. This oral formulation offers an effective alternative to erythropoiesis-stimulating agents (ESAs), particularly in patients undergoing dialysis or those with non-dialysis-dependent CKD. Oxemia 100 is administered once daily, with dosage adjustments based on hemoglobin response and clinical condition. Clinical trials have demonstrated its efficacy in increasing hemoglobin concentrations while maintaining a favorable safety profile. Common adverse effects may include mild gastrointestinal disturbances, headache, and hypertension; however, serious adverse events are infrequent. Caution is advised in patients with uncontrolled hypertension or cardiovascular disease. Regular monitoring of hemoglobin, iron status, and blood pressure is recommended during therapy. Oxemia 100 should be used under medical supervision, ensuring appropriate dose titration to minimize risks of excessive erythropoiesis and thromboembolic events. This medication represents a significant advancement in anemia management, improving patient outcomes and quality of life in CKD-related anemia.